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Abstract
Introduction
Dogs with protein-losing enteropathy (PLE) have decreased serum tryptophan concentra-
tions, which may contribute to disease pathogenesis. Indoleamine-pyrrole 2,3-dioxygenase-
1 (IDO-1) expression is associated with low serum tryptophan concentrations and is
increased in the gastrointestinal tract of humans with inflammatory bowel disease (IBD).
Therefore, the objective of our study was to determine if the mRNA expression of IDO-1 is
increased in the duodenal mucosa of dogs with PLE as compared to dogs with chronic
enteropathy (CE) and healthy dogs, and whether this expression is correlated with changes
in serum tryptophan concentration.
Methods
Our study was a retrospective study using archived paraffin-embedded duodenal biopsy
specimens from 8 healthy Beagle dogs from the Iowa State University Canine Service Col-
ony and 18 and 6 client-owned dogs diagnosed with CE and PLE, respectively at the Bristol
Veterinary School. A novel RNA in situ hybridization (ISH) technology, RNAscope, was
used to identify IDO-1 mRNA mucosal expression in duodenal tissues. An IDO-1 specific
probe was hybridized onto 10 duodenal biopsy sections from each dog whereby RNAscope
signal (mRNA expression) was quantified by a single operator using light microscopy.
Results
Dogs with PLE had significantly higher mRNA expression of IDO-1 in the duodenal mucosa
compared to healthy dogs (mucosal percentage IDO-1 positive: P = 0.0093, (mean ± S.D)
control: 19.36 ± 7.08, PLE: 34.12 ± 5.98, average fold difference: 1.76 and mucosal IDO-1
PLOS ONE | https://doi.org/10.1371/journal.pone.0218218 June 10, 2019 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Kathrani A, Lezcano V, Hall EJ, Jergens
AE, Seo Y-J, Mochel JP, et al. (2019) Indoleamine-
pyrrole 2,3-dioxygenase-1 (IDO-1) mRNA is over-
expressed in the duodenal mucosa and is
negatively correlated with serum tryptophan
concentrations in dogs with protein-losing
enteropathy. PLoS ONE 14(6): e0218218. https://
doi.org/10.1371/journal.pone.0218218
Editor: Simon Russell Clegg, University of Lincoln,
UNITED KINGDOM
Received: April 1, 2019
Accepted: May 28, 2019
Published: June 10, 2019
Copyright: © 2019 Kathrani et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
H-score: P = 0.0356, (mean ± S.D) control: 45.26 ± 19.33, PLE: 84.37 ± 19.86, average fold
difference: 1.86). The duodenal mucosal mRNA expression of IDO-1 was negatively corre-
lated with serum tryptophan concentrations in dogs with PLE (mucosal IDO-1 H-score:
Spearman’s rank correlation coefficient = -0.94, P = 0.0048).
Conclusions
In conclusion, our study suggests that decreased serum tryptophan concentrations in dogs
with PLE is associated with increased intestinal IDO-1 expression. Further studies are
needed to determine potential inflammatory pathways responsible for increased expression
of IDO-1 in the intestinal tract of dogs with PLE.
Introduction
Indoleamine-pyrrole 2,3-dioxygenase-1 (IDO-1) is an enzyme expressed by cells of the
innate immune system and acts as the interface with the adaptive immune system [1]. IDO-
1 promotes immune tolerance by influencing T-cell proliferation and clonal expansion and
has also been shown to have antimicrobial properties [1, 2]. Toll-like receptor activation as
well as pro-inflammatory cytokines, such as interferon-gamma and tumor necrosis factor-
alpha, may induce IDO-1 expression [1, 3]. Therefore, IDO-1 expression is increased in the
gastrointestinal (GI) tract of both humans with inflammatory bowel disease (IBD) and ani-
mal models of colitis, due to overexpression of pro-inflammatory cytokines and over-activa-
tion of toll-like receptors [4–6]. IDO-1 is also the initial rate-limiting step in the pathway
for the oxidation of tryptophan to kynurenine [7]. Therefore, increased IDO-1 expression is
associated with lower serum tryptophan concentrations in humans with IBD due to
increased tryptophan catabolism [8].
Recently, dogs with protein-losing enteropathy (PLE) have been documented to have sig-
nificantly lower serum tryptophan concentrations compared to healthy dogs [9]. Tryptophan
is a dietary essential amino acid in dogs and is important for protein synthesis as well as serv-
ing as a precursor for bioactive compounds, such as kynurenine, serotonin, melatonin and
picolinic acid [7]. Endogenous tryptophan metabolites have been shown to protect from
mucosal inflammation by maintaining gut immune homeostasis and microbial diversity in
animal models of colitis [10, 11]. Furthermore, tryptophan-deficient mice showed more severe
colitis when administered oral dextran sodium sulfate [12]. Hence, tryptophan is important in
helping regulate beneficial physiological functions and reduce mucosal injury in the GI tract
[13, 14]. Consequently, decreased serum tryptophan concentrations in dogs with PLE might
contribute to or aggravate intestinal inflammation. Further studies are needed to determine
the pathomechanism of decreased serum tryptophan concentrations and to provide insight
into those treatment modalities likely to restore tryptophan concentrations in dogs with PLE.
Collectively, studies in humans with IBD and experimental models of colitis suggest that
decreased serum tryptophan concentration in dogs with PLE might be due to increased
intestinal IDO-1 expression causing increased catabolism of tryptophan. However, IDO-1
expression has not been previously assessed in the intestinal mucosa of dogs with PLE.
Therefore, our study aimed to determine whether mRNA expression of IDO-1 is altered in
the duodenal mucosa of dogs with PLE compared to dogs with chronic enteropathy (CE)
and healthy dogs, and whether this expression correlated with serum tryptophan concen-
trations in dogs with PLE.
IDO-1 expression in canine enteropathy
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Materials and methods
Study design
We performed a retrospective study using archived paraffin-embedded duodenal biopsy speci-
mens obtained from dogs with PLE or CE referred to the University of Bristol. Tissue specimens
from three groups of dogs were studied: PLE (n = 6), CE (n = 18) and healthy controls (n = 8)
comprising a population of young adult Beagle dogs at the Iowa State University.
Retrospective study criteria for case selection
Six dogs diagnosed with PLE at the Bristol Veterinary School that previously had serum trypto-
phan concentrations measured as part of a separate study were specifically chosen [9]. Diagnostic
evaluations performed on all 6 dogs included a complete blood count, serum biochemistry,
serum cobalamin and folate concentrations, pre- or pre- and post- prandial bile acid concentra-
tions, urine protein creatinine ratio, empirical deworming, trans-abdominal ultrasound examina-
tion and gastrointestinal endoscopy and histopathology of intestinal biopsies. Of the 6 dogs
included in the PLE group, the following number had additional diagnostic procedures per-
formed: pancreatic testing (canine pancreatic lipase immunoreactivity in 3 dogs and trypsin-like
immunoreactivity in 3, basal cortisol concentration or ACTH stimulation test in 4 dogs, fecal par-
asitology using zinc sulfate flotation with centrifugation in 5 dogs, and fecal culture (for Salmo-
nella, Campylobacter and Clostridium difficile) in 5 dogs. The albumin concentrations of these 6
dogs ranged from 13.7 to 19.8 g/L (laboratory reference range (32–38) with a median of 15.2 g/L.
The medical records at the Bristol Veterinary School were searched for dogs that had been
diagnosed with CE but without biochemical abnormalities consistent with PLE (panhypoproteine-
mia with an albumin concentration of less than 32 g/L or solely hypoalbuminemia with a concen-
tration of less than 25 g/L were used as exclusion criteria). All medical records then were reviewed
by 1 of the authors (AK). Only dogs with a histologic diagnosis of chronic inflammatory enteropa-
thy that had adequate and appropriate investigations to exclude other causes of chronic GI signs
before histologic diagnosis were included. Diagnostic evaluations performed on all 16 dogs
included a complete blood count, serum biochemistry and gastrointestinal endoscopy and histo-
pathology of intestinal biopsies. Of the 16 dogs included in the CE group, the following number
had the following diagnostic procedures performed: abdominal imaging with either trans-abdom-
inal ultrasound examination in 14 dogs or computed tomography in 1 dog, pancreatic testing
(canine pancreatic lipase immunoreactivity in 7 dogs and trypsin-like immunoreactivity in 8,
basal cortisol concentration or ACTH stimulation test in 10 dogs, pre- or pre- and post- prandial
bile acid concentrations in 7 dogs, fecal parasitology using zinc sulfate flotation with centrifugation
in 5 dogs and fecal culture (for Salmonella, Campylobacter and Clostridium difficile) in 4 dogs.
The canine chronic enteropathy activity index (CCEAI) [15], which is based on the pres-
ence and severity of nine factors including attitude/activity, appetite, vomiting, stool consis-
tency, stool frequency, weight loss, serum albumin concentrations, ascites and peripheral
edema and pruritus was retrospectively calculated for each dog based on the history collected
at admission and the referring veterinarian’s medical records.
Archived paraffin embedded duodenal biopsies were retrieved from the archive at Bristol
Veterinary School from the selected cases and at least 10 serial sections, mounted onto glass
slides from each dog were sent to Iowa State University for IDO-1 RNA in situ hybridization.
Selection of control dogs
The research colony of the Iowa State University Center of Veterinary Medicine (8 female
spayed Beagle dogs at 2 years of age) was used to obtain endoscopic intestinal biopsies from
IDO-1 expression in canine enteropathy
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healthy control dogs. The dogs were housed in groups of 4 per kennel with access to outside
and behavioral enrichment with training provided by veterinary students three times per
week. They were fed a commercial dog food twice per day with ad libitum access to water and
each dog was assessed daily for health by a veterinarian. The dogs were assessed as clinically
healthy and had a complete blood count, serum biochemistry, urinalysis, and fecal parasitology
performed, which were all normal. Gastrointestinal endoscopy was performed under general
anaesthesia and buprenorphine was administered as an analgesic; all procedures were per-
formed at the veterinary hospital at the Iowa State University. All dogs were adopted after the
study.
RNA in situ hybridization
RNA in situ hybridization (ISH) allows the detection of specific RNA sequences with cellular
resolution within tissue architecture on routine formalin-fixed, paraffin-embedded tissue spec-
imens. Specifically, a novel RNA ISH technology, RNAscope (ACD Biotech, Newark, CA),
which provides single-molecule visualization while preserving tissue morphology was used for
diagnostic purposes. Two slides with 5 or more duodenal biopsies per dog each were hybrid-
ized with the IDO-1 mRNA specific probes and examined, including use of positive controls
for each hybridization using Ubiquitin C. Preparation and hybridization of the slides was done
in accordance to the user manual protocol provided by Advanced Cell Diagnostics (ACD)
Biotech.
Visualization and image capture
RNAscope signals were first visualized by using a 20x Plan N lens on an Olympus BX40 micro-
scope (Olympus Optical Co., LTD, Japan) and photographed with an Olympus DP27 camera
(Olympus Optical Co., LTD, Japan). Ten images were obtained from different representative
fields per glass slide. A representative mucosal field was defined as containing 3 or more duo-
denal biopsy specimens containing at least 3 contiguous villi for diagnostic evaluation [16].
Quantitative analysis of IDO-1 expression
Quantitative assessment of IDO-1 mRNA expression was performed utilizing the images cap-
tured and was performed by a single operator (VL). The quantitative assessment consisted of
average mucosal IDO-1 copies per cell, average mucosal IDO-1 area per cell, mucosal percent-
age IDO-1 positive and mucosal IDO-1 H-score for all dogs. H-scores were calculated using
RNAscope technology and digital quantitation by HALO using the data analysis guide pro-
vided by ACD Biotech.
Serum tryptophan concentrations in dogs with PLE
Serum collected at the time of diagnosis from the 6 dogs with PLE had previously been ana-
lyzed for tryptophan using an automated high-performance liquid chromatography amino
acid analyzer as part of a previous study [9]. None of the dogs with CE or healthy controls had
serum tryptophan measurements performed.
Ethical considerations
Archived paraffin-embedded duodenal biopsies were used in this study and the University of
Bristol granted ethical approval for the study (VIN/18/014). Iowa State University granted eth-
ical approval for the use of paraffin-embedded duodenal biopsies from healthy colony Beagle
dogs (9-17-8605-K).
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Data analysis and statistics
One-way analysis of variance (ANOVA) was used to assess differences in mean values for the
mRNA expression of IDO-1 in the duodenal mucosa (average mucosal IDO-1 copies per cell,
average mucosal IDO-1 area per cell, percentage mucosal IDO-1 positive and mucosal IDO-1
H-score) between the three groups of dogs (PLE, CE and Control). If significant difference was
identified among the groups, post-hoc pairwise comparisons test was performed using Tukey’s
HSD (Honestly Significant Difference). The Spearman’s Rank correlation test was used to
determine if there was a significant correlation between mRNA expression of IDO-1 in the
duodenal mucosa and serum tryptophan concentrations in dogs with PLE. Analyses were per-
formed using R software version 3.5.2 (R Foundation for Statistical Computing, Vienna, Aus-
tria) and IBM SPSS Statistics Version 24. Statistical significance was defined as P< 0.05.
Results
Dogs
Six dogs with PLE were included; 4 female neutered and 2 male neutered dogs, with a median
age of 8.0 years and a range of 3.5 to 12. There were 2 Labrador retrievers and one each of the
following breeds: Japanese Akita, Staffordshire bull terrier, border terrier and Jack Russell ter-
rier. The median CCEAI was 9 (severe disease activity) with a range of 4 to 15. Two dogs were
diagnosed with lymphoplasmacytic and eosinophilic enteritis, three with lymphoplasmacytic
enteritis and one with lymphoplasmacytic, neutrophilic and eosinophilic enteritis.
Eighteen dogs with CE were included; 10 female neutered, 7 male neutered and one male
intact dog, with a median age of 6.7 years and a range of 0.8 to 11. There were 8 German shep-
herd dogs, 2 Border collies, 2 Boxers and one each of the following breeds: West Highland
white terrier, Beagle, Siberian husky, Chihuahua, Border terrier and Cavalier King Charles
spaniel. The median CCEAI was 8.5 (moderate disease activity) with a range of 3 to 13. Seven
dogs were diagnosed with eosinophilic enteritis, 4 dogs with lymphoplasmacytic, eosinophilic
and neutrophilic enteritis, 3 dogs with lymphoplasmacytic and eosinophilic enteritis, 2 dogs
with lymphoplasmacytic enteritis, one with lymphocytic enteritis and one with plasmacytic
enteritis.
There were no significant differences in age or CCEAI between the PLE and CE groups (P
>0.204).
Eight healthy Beagle control dogs were included; all were female and 2 years of age.
IDO-1 mRNA
One-way ANOVA comparing the mRNA expression of IDO-1 in the duodenal mucosa (aver-
age mucosal IDO-1 copies per cell, average mucosal IDO-1 area per cell, percentage mucosal
IDO-1 positive and mucosal IDO-1 H-score) between the three groups of dogs (PLE, CE and
Control) showed a significant difference in percentage mucosal IDO-1 positive mRNA and
mucosal IDO-1 H-score between the three groups (P = 0.0123 and 0.0435, respectively). How-
ever, average mucosal IDO-1 copies per cell and average mucosal IDO-1 area per cell were not
significantly different between the three groups.
Tukey’s post-hoc analysis revealed that dogs with PLE have significantly higher mucosal
IDO-1 percentage positive mRNA and mucosal IDO-1 H-score in the duodenum compared to
healthy Beagle dogs (IDO-1 percentage positive mRNA: P = 0.0093, mean (± standard devia-
tion); PLE– 34.12 (± 5.98); Control—19.36 (± 7.08); mucosal IDO-1 H-score; P = 0.0356, PLE–
84.37 (± 19.86); Control– 45.26 (± 19.33); Table 1 and Figs 1, 2, 3 and 4). There were no signifi-
cant differences for the remainder of the 2 parameters between dogs with PLE and healthy
IDO-1 expression in canine enteropathy
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Beagle dogs and for none of the 4 parameters between dogs with PLE and CE and between
dogs with CE and healthy Beagle dogs (Table 1).
Correlation between duodenal mucosal IDO-1 mRNA and serum
tryptophan concentrations in dogs with PLE
The mRNA expression of IDO-1 in the duodenal mucosa was negatively correlated with
serum tryptophan concentrations in dogs with PLE (average mucosal IDO-1 copies per cell:
Spearman’s rank correlation coefficient (SRCC) = -0.94, P = 0.0048, average mucosal IDO-1
Table 1. Post hoc analysis of IDO-1 mRNA expression in the duodenal mucosa of dogs with protein-losing enteropathy (PLE), chronic enteropathy (CE), and
healthy Beagle control dogs using RNA in situ hybridization. P-values obtained from Tukey’s HSD (Honestly Significant Difference) post-hoc analysis after one-way
analysis of variance testing of percentage mucosal IDO-1 positive mRNA and IDO-1 H-score in the duodenal mucosa of dogs with PLE (n = 6), dogs with CE (n = 18) and
healthy Beagle control dogs (n = 8).
Group comparisons Difference in means 95% confidence interval for mean difference Adjusted p-value
(Tukey’s HSD)
Percentage mucosal IDO-1 positive CE—Healthy 7.364 (-1.637, 16.365) 0.1253
PLE—Healthy 14.768 (3.327, 26.208) 0.0093�
PLE—CE 7.404 (-2.582, 17.390) 0.1774
Mucosal IDO-1 H-score CE—Healthy 20.104 (-8.859, 49.066) 0.2171
PLE—Healthy 39.105 (2.294, 75.916) 0.0356�
PLE—CE 19.001 (-13.130, 51.133) 0.3243
Significance was defined as P < 0.05
�
.
https://doi.org/10.1371/journal.pone.0218218.t001
Fig 1. Box and whisker plot of percentage mucosal IDO-1 positive mRNA in the duodenum of dogs with protein-
losing enteropathy (PLE), chronic enteropathy (CE) and healthy Beagle dogs. Dogs with PLE– 6 dogs, median–
32.18, interquartile range- 11.19. Dogs with CE– 18 dogs, median– 25.28, interquartile range- 9.56, healthy Beagle
control dogs- 8 dogs, median– 19.65, interquartile range- 11.44.
https://doi.org/10.1371/journal.pone.0218218.g001
IDO-1 expression in canine enteropathy
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area per cell: SRCC = -0.89, P = 0.019, percentage mucosal IDO-1 positive: SRCC = -0.83,
p = 0.042, mucosal IDO-1 H-score: SRCC = -0.94, P = 0.0048; Fig 5).
Discussion
In this study, we show that dogs with PLE have significantly higher percentage mucosal IDO-1
positive mRNA and mucosal IDO-1 H-score in the duodenum compared to healthy Beagle
control dogs. IDO-1 is the first and rate-limiting step in the catabolism of tryptophan in the
kynurenine pathway [17, 18]. Through the catabolism of tryptophan and the generation of
kynurenine metabolites, IDO-1 plays an important role in mucosal immune tolerance [19].
IDO-1 activity promotes depletion of tryptophan in the microenvironment, which induces cell
cycle arrest of T-cells and increases their apoptosis [20]. However, recent evidence suggests
that in a normal environment containing fatty acids, the immunosuppressive effect of IDO
might not be due to decreased T cell survival and proliferation, as IDO supplied the required
energy for cell survival and proliferation by increasing fatty acid oxidation [21]. Nevertheless,
the catabolism of tryptophan via IDO-1 also leads to the generation of immune-modulating
kynurenine metabolites [22]. These metabolites induce tolerogenic dendritic cells as well as T
regulatory cells [23–25]. Kynurenine also selectively activates the transcription of aryl hydro-
carbon, which results in the differentiation of CD4+ T cell into immunosuppressive T regula-
tory cells [26]. IDO- 1 also possesses a non-enzymatic function that contributes to TGF-beta
led tolerance [27]. Therefore, IDO-1 expressing antigen presenting cells are crucial in sup-
pressing pro-inflammatory mucosal T-cells that drive chronic intestinal inflammation. Epithe-
lial IDO-1 activity may also function to limit microbial invasion as IL-27 has been shown to
inhibit growth of intestinal bacteria and promote epithelial barrier protection via induction of
Fig 2. Box and whisker plot of mucosal IDO-1 H-score in the duodenum of dogs with protein-losing enteropathy
(PLE), chronic enteropathy (CE) and healthy Beagle dogs. Dogs with PLE– 6 dogs, median– 77.66, interquartile
range- 40.18. Dogs with CE– 18 dogs, median– 58.69, interquartile range- 26.82, healthy Beagle control dogs- 8 dogs,
median– 45.26, interquartile range- 31.68.
https://doi.org/10.1371/journal.pone.0218218.g002
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IDO-1 in human and mouse intestinal epithelial cells [28]. Therefore, intestinal IDO-1 acts as
a natural brake to inflammatory responses via the metabolism of tryptophan.
IDO-1 expression is stimulated by proinflammatory cytokines including interferon
gamma, tumor necrosis factor-alpha and interleukin-1 beta and activation of toll-like receptors
[2, 29, 30]. In line with this notion, IDO-1 is one of the most up-regulated genes in human
IBD and animal models of colitis [4, 31, 32]. Also, several studies have documented increased
intestinal IDO-1 mRNA and protein in human and animal models of IBD [6, 33, 34]. Consis-
tent with these earlier studies, our results also showed increased IDO-1 mRNA in the duodenal
mucosa of dogs with PLE compared to healthy Beagle dogs. This upregulation of duodenal
IDO-1 mRNA in dogs with PLE is likely reflective of increased inflammation and immune
activation within the duodenum. Interestingly, our study did not document a difference in
IDO-1 mRNA expression in the duodenal mucosa between dogs with CE and healthy Beagle
control dogs. There could be a number of possibilities for this finding. First, our study used a
Fig 3. RNA in situ hybridization of IDO-1 mRNA in the duodenal mucosa of a dog with protein-losing enteropathy.
https://doi.org/10.1371/journal.pone.0218218.g003
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relatively small number of dogs, which could have reduced the statistical power of the analysis;
second, the immunological pathogenesis of CE and PLE may be different, which could explain
the lack of a significant difference in dogs with CE; and third, most of the dogs with CE in our
study were German shepherd dogs which may have breed-specific patterns of cytokine expres-
sion, as suggested by recent investigations on the role of Th2 cytokines in the pathogenesis of
CE in this breed [35]. Interestingly, one study showed that exposure of peripheral blood mono-
nuclear cells to Th2 cytokines resulted in higher tryptophan concentrations as the breakdown
of this amino acid was suppressed [36]. Th2 cytokines counteract interferon-gamma and other
Th1 mediated cytokines and therefore this may result in lower IDO-1 expression. Therefore,
as nearly half of the dogs in the CE group were German shepherd dogs, which may have a Th2
driven inflammatory process for their CE, this might potentially explain why dogs with CE in
our study did not have significantly increased IDO-1 mRNA expression compared to healthy
Fig 4. RNA in situ hybridization of IDO-1 mRNA in the duodenal mucosa of a healthy Beagle control dog.
https://doi.org/10.1371/journal.pone.0218218.g004
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controls. However, further studies are needed to determine which specific proinflammatory
cytokine(s) promote increased IDO-1 mRNA expression in dogs with PLE.
Although, IDO-1 is increased in the intestinal tract of humans and mouse models of IBD,
studies suggest a beneficial role for this upregulation. IDO-1 knockout mice exhibit worse coli-
tis, T-cell infiltration and mortality [37]. Also, disease severity was worsened in mice with tri-
nitrobenzenesulfonic acid induced colitis receiving IDO-1 inhibition [5]. On the other hand,
induction of IDO-1 reduced colon injury and ameliorated lethality in graft-versus-host disease
in mice [38]. Collectively, these findings suggest that IDO-1 functions as a negative feedback
mechanism to limit the development of chronic inflammation. Therefore, the increased IDO-
1 expression likely represents an anti-inflammatory mechanism to counterbalance the pro-
inflammatory milieu causing intestinal inflammation. Hence, the expression of IDO-1 could
be an indicator of the level of intestinal inflammation due to this counter-regulatory response.
Fig 5. Scatter plot of serum tryptophan concentrations and duodenal mucosal IDO-1 H-score in dogs with protein-losing enteropathy. Scatter plot of serum
tryptophan concentrations (nmol/ml) and duodenal mucosal IDO-1 H-score of 6 dogs with protein-losing enteropathy (PLE). Serum tryptophan concentrations were
significantly negatively correlated with mucosal IDO-1 H-score in dogs with PLE (Spearman’s rank correlation co-efficient: -0.94, P = 0.0048).
https://doi.org/10.1371/journal.pone.0218218.g005
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Unfortunately, due to the small number of dogs in our study, correlations with severity of duo-
denal histopathology or clinical disease activity could not be performed to determine if duode-
nal IDO-1 mRNA expression increases with disease severity in dogs with PLE. Future studies
should focus on determining if such correlations exist, as intestinal IDO-1 mRNA expression
could then be used as a marker of clinical and histological severity in dogs with PLE.
Increased IDO-1 expression in the intestinal mucosa also decreases serum tryptophan con-
centrations and increases kynurenine concentrations in patients with Crohn’s disease a type of
IBD in humans [8]. Our study showed similar findings of a negative correlation between duo-
denal IDO-1 mRNA expression and serum tryptophan concentration in dogs with PLE. We
have previously shown that dogs with PLE have significantly lower serum tryptophan concen-
trations compared to healthy dogs [9]. Results from our current study suggest that decreased
serum tryptophan concentrations in dogs with PLE might be due to accelerated catabolism of
this amino acid from increased intestinal IDO-1 expression. The kynurenine-to-tryptophan
ratio, which is an indicator of IDO-1 activation in the intestinal tract, has been shown to be
negatively correlated with Crohn’s disease activity [8]. Unfortunately, due to the small number
of PLE dogs included in our study and the absence of serum kynurenine concentration mea-
surements in these dogs, similar conclusions could not be made with regards to clinical disease
activity. However, further studies should assess whether serum concentrations of tryptophan
and kynurenine metabolites could serve as a useful biomarker of intestinal mucosal inflamma-
tion and immune activation in dogs with PLE.
Another explanation for a negative correlation between serum tryptophan concentration
and duodenal IDO-1 mRNA expression in dogs with PLE could be due to increased IDO-1
mRNA expression from worsening intestinal inflammation leading to increased enteric albu-
min loss, which could lead to reduced serum tryptophan concentrations. However, our study
measured only free tryptophan in serum and therefore is unlikely to have been directly affected
by the serum albumin concentrations. Also, serum concentrations of free tryptophan in
humans with chronic renal failure were shown to be uninfluenced by serum protein concen-
trations and the free fraction was normal in those patients with hypoalbuminemia [39]. There-
fore, increased enteric albumin loss is unlikely to be a cause for the negative correlation
between duodenal IDO-1 mRNA expression and serum tryptophan concentration in dogs
with PLE. Similarly, we have previously documented that appetite (anorexic, hyporexic,
unchanged or increased) did not significantly affect serum tryptophan concentrations in dogs
with PLE [9].
Dogs with PLE can have poor prognosis following failure with immunomodulatory therapy
[40]. Pharmacologic agents, which inhibit or potentiate IDO-1 expression and activity, may
have the potential as treatment for dogs with PLE. However, upregulation of IDO-1 might
function as a regulatory mechanism to suppress immune response and protect intestinal
mucosal tissue [6, 34]. Therefore, further studies are needed to determine the role of increased
IDO-1 expression in dogs with PLE before any recommendations can be made regarding
inhibiting or potentiating this enzyme in the potential treatment of this disease.
Potential limitations of our study include the use of partial thickness endoscopic biopsies
for RNA ISH rather than full-thickness biopsies, possibly missing cells expressing IDO-1
mRNA in the deeper mucosa. In addition, our study exclusively assessed mRNA levels and
provides no information on protein expression per se. In other words, the production of the
IDO-1 protein could have been unaltered despite the increase in mRNA expression. Addition-
ally, our study only included mRNA expression data from the duodenum, such that expression
in other intestinal segments where tryptophan absorption may occur e.g. the ileum may have
shown different results. Finally, dogs with CE in our study did not have serum tryptophan
IDO-1 expression in canine enteropathy
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concentrations assessed, therefore unlike the PLE group, correlations regarding serum trypto-
phan concentration and duodenal mucosal IDO-1 mRNA expression could not be performed.
In conclusion, our study demonstrates that dogs with PLE have increased mRNA expres-
sion of IDO-1 in the duodenal mucosa compared to healthy Beagle dogs and this negatively
correlated with serum tryptophan concentrations. Further studies are needed to determine the
role of increased IDO-1 expression in the duodenum of dogs with PLE, as well as the inflam-
matory pathways responsible for the increased expression of IDO-1.
Supporting information
S1 File. Excel sheet of IDO-1 mRNA expression in the duodenal mucosa of all dogs. Results
of the average mucosal IDO-1 copies per cell, average mucosal IDO-1 area per cell, percentage
mucosal IDO-1 positive and mucosal IDO-1 H-score for all dogs included in the study and
serum tryptophan concentrations for the 6 dogs diagnosed with PLE.
(XLSX)
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